Osman Yasser, Kamal Mohamed, Soliman Shady, Sheashaa Hussein, Shokeir Ahmed, Shehab el-Dein Ahmed B
Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Urology. 2007 Apr;69(4):647-51. doi: 10.1016/j.urology.2006.12.017.
To determine the exact value of postoperative heparinization in preventing thrombotic sequelae in non-risky renal transplants and to assess the possible hazards of this therapy through a prospective randomized trial.
Of 120 consecutive live-donor renal transplants, 45 patients were excluded because of young age, multiple or atheromatous graft arteries, a history of thromboembolic disease, or intraoperative technical difficulties. The remaining patients were prospectively randomized into three groups, with 25 patients each. Group 1 did not undergo heparinization. Groups 2 and 3 received a prophylactic dose of low-molecular-weight heparin and conventional heparin, respectively, for 1 week.
None of our patients in any group developed graft vascular thrombosis, deep venous thrombosis, or pulmonary embolism, and the rate of spontaneous closure of arteriovenous fistulas was comparable among the three groups (P = 0.79). No statistically significant difference was found among the three groups in terms of the development of significant perirenal hematomas, rate of blood transfusions, or mean number of transfused units (P = 0.37, P = 0.56, and P = 0.69, respectively). In contrast, a significant decrease in the hemoglobin level occurred in group 3 compared with group 1 among nontransfused patients (1.6 +/- 0.8 g% and 0.7 +/- 0.9 g%, respectively; P = 0.01). Moreover, a significant shortening of lymph drainage time and a reduction of the total amount of lymphorrhea were found in group 1 compared with groups 2 and 3 (P = 0.01, P = 0.03, respectively).
Postoperative heparinization should not be routinely indicated in non-risky live-donor renal transplantation.
通过一项前瞻性随机试验,确定术后肝素化在预防非高危肾移植血栓形成后遗症方面的准确价值,并评估该治疗方法可能存在的风险。
在连续的120例活体供肾肾移植患者中,45例因年龄过小、移植肾动脉多发或有粥样硬化、有血栓栓塞病史或术中技术困难而被排除。其余患者被前瞻性随机分为三组,每组25例。第1组未接受肝素化治疗。第2组和第3组分别接受预防性剂量的低分子量肝素和常规肝素治疗,持续1周。
我们三组中的任何患者均未发生移植肾血管血栓形成、深静脉血栓形成或肺栓塞,三组间动静脉瘘的自发闭合率相当(P = 0.79)。三组在严重肾周血肿的发生、输血率或平均输血量方面均未发现统计学上的显著差异(分别为P = 0.37、P = 0.56和P = 0.69)。相比之下,在未输血的患者中,第3组的血红蛋白水平与第1组相比有显著下降(分别为1.6 +/- 0.8 g%和0.7 +/- 0.9 g%;P = 0.01)。此外,与第2组和第3组相比,第1组的淋巴引流时间显著缩短,淋巴液总量减少(分别为P = 0.01、P = 0.03)。
在非高危活体供肾肾移植中,术后不应常规进行肝素化治疗。